Please use this identifier to cite or link to this item: https://doi.org/10.1038/leu.2011.53
DC FieldValue
dc.titleClinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma
dc.contributor.authorChng, W.-J.
dc.contributor.authorHuang, G.F.
dc.contributor.authorChung, T.H.
dc.contributor.authorNg, S.B.
dc.contributor.authorGonzalez-Paz, N.
dc.contributor.authorTroska-Price, T.
dc.contributor.authorMulligan, G.
dc.contributor.authorChesi, M.
dc.contributor.authorBergsagel, P.L.
dc.contributor.authorFonseca, R.
dc.date.accessioned2014-11-26T09:59:32Z
dc.date.available2014-11-26T09:59:32Z
dc.date.issued2011-06
dc.identifier.citationChng, W.-J., Huang, G.F., Chung, T.H., Ng, S.B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P.L., Fonseca, R. (2011-06). Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25 (6) : 1026-1035. ScholarBank@NUS Repository. https://doi.org/10.1038/leu.2011.53
dc.identifier.issn08876924
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/110728
dc.description.abstractEvents mediating transformation from the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are unknown. We analyzed gene expression data sets generated on the Affymetrix U133 platform from 22 MGUS and 101 MM patients using gene-set enrichment analysis. Genes overexpressed in MM were enriched for cell cycle, proliferation and MYC activation gene sets. Upon dissecting the relationship between MYC and cell-cycle gene sets, we identified and validated an MYC activation signature dissociated from proliferation. Applying this signature, MYC is activated in 67% of myeloma, but not in MGUS. This was further confirmed by immunohistochemistry (IHC) using membrane CD138 and nuclear MYC double staining. We also showed that almost all tumors with RAS mutations expressed the MYC activation signature, and multiple mechanisms may be involved in activating MYC. MYC activation, whether assessed by gene-expression signature or IHC, is associated with hyperdiploid MM and shorter survival even in tumors that are not proliferative. Bortezomib treatment is able to overcome the survival disadvantage in patients with MYC activation. © 2011 Macmillan Publishers Limited All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1038/leu.2011.53
dc.sourceScopus
dc.subjectbortezomib
dc.subjecthyperdiploid
dc.subjectMGUS
dc.subjectMYC
dc.subjectmyeloma
dc.typeArticle
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.1038/leu.2011.53
dc.description.sourcetitleLeukemia
dc.description.volume25
dc.description.issue6
dc.description.page1026-1035
dc.description.codenLEUKE
dc.identifier.isiut000291386900017
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

186
checked on Nov 19, 2021

WEB OF SCIENCETM
Citations

184
checked on Nov 19, 2021

Page view(s)

139
checked on Nov 18, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.